findmyKOL
Clinical trialNCT04841148RecruitingPhase 2Interventional

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

SponsorAbramson Cancer Center at Penn MedicineEnrollment96Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Georgetown University

    Washington D.C., District of Columbia, United States

    Recruiting
  • University of Chicago

    Chicago, Illinois, United States

    Recruiting
  • Indiana University

    Indianapolis, Indiana, United States

    Recruiting
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Recruiting
  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

    Recruiting
  • Vanderbilt University

    Nashville, Tennessee, United States

    Recruiting
  • University of Washington

    Seattle, Washington, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Avelumab →HCQPalbociclib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Jun 2021
Primary completion
31 Jul 2027
Completion
31 May 2028
Last update posted
9 Apr 2026
Registered enrollment
96
Registry id
NCT04841148
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.